iORGAN Tech, a company specializing in induced pluripotent stem cell (iPSC)-derived organoids in SIP, recently announced good news: obtaining the approval for the recognition of two national major science and technology projects in collaboration with top clinical scientists, and successfully commercializing its iPSC-derived organoids through partnerships with pharmaceutical companies and medical institutions.

“We have entered the fast track to industrialization. This stems from both our technological innovation and SIP’s comprehensive support in policy, funding and services,” said co-founder Wan Fei.

Since the establishment of the company, SIP Enterprise Development Service Center and other departments have provided considerate and efficient assistance in site selection, application for benefits under preferential policies, R&D and partnership facilitation, consistently bridging its R&D achievements with market.

December 3, 2025